CB1 Receptor Baseline — How Natural Cannabinoids Bind
THC and anandamide set the natural benchmark for CB1 signaling.
- GPCR: CB1 receptor type (Gi/o-coupled)
- Partial: THC intrinsic efficacy (~40% max signal)
- Ki ~ nM: Anandamide affinity (endogenous ligand)
- CNS-wide: Distribution (dense in brain, low peripheral)
CB1 as a partial-agonist baseline
THC only partially activates CB1, capping its own high.
Why baseline matters for comparison
Every synthetic compound is judged against this natural ceiling.
Dronabinol — Precisely Dosed Synthetic THC
Dronabinol is lab-made THC, dosed and labeled for medical use.
- Marinol: Brand name (FDA-approved 1985)
- CINV, appetite: Indication (chemo nausea, HIV wasting)
- 2.5–10 mg: Dose precision (known capsule strength)
- Partial: Agonist type (THC-like profile)
Controlled dosing, controlled effect
Fixed capsule strength keeps receptor response predictable and mild.
Clinical role
Used under supervision for nausea and appetite, not recreation.
"Spice" / K2 — Unregulated Full CB1 Agonists
Street synthetic cannabinoids bind CB1 far harder than THC.
- Full: Agonist type (near-100% efficacy)
- 2–100×: Relative potency (vs. natural THC)
- None: Dose labeling (sprayed unevenly on plant matter)
- Variable: Composition (batch-to-batch chemistry shifts)
Full agonism overwhelms the receptor
Near-maximal CB1 activation drives severe, unpredictable physiological effects.
No dose control, no safety margin
Unlabeled potency means users cannot gauge a safe amount.
Predictable Medicine vs. Unpredictable Street Chemistry
Same receptor, wildly different outcomes depending on the source.
- Predictable: Pharmaceutical outcome (known dose, known effect)
- Unpredictable: Illicit outcome (unknown dose, variable effect)
- Thousands/yr: Reported illicit ER events (US poison-control data)
- Psychosis, seizures: Severe reactions (cardiac events reported)
Two very different risk curves
One stays flat and safe; the other spikes unpredictably.
Severity scales with unregulated potency
Higher illicit binding efficacy drives sharper adverse-effect spikes.
Why "Synthetic Marijuana" Is Not Medical Cannabinoid Therapy
Shared naming masks a stark pharmacological safety gap.
- Established: Pharmaceutical safety record (decades of clinical use)
- Poor: Illicit safety record (unregulated, high-variance)
- Naming: Public confusion driver ("synthetic marijuana" misnomer)
- Regulation matters: Core takeaway (dose and purity define risk)
Regulation is the dividing line
Dosed pharmaceuticals and unregulated street drugs are not equivalent.
Takeaway for public understanding
Naming similarity should not imply similar safety.